Zacks Investment Research upgraded shares of Amyris (NASDAQ:AMRS) from a sell rating to a hold rating in a research report report published on Tuesday morning.
According to Zacks, “Amyris INC is an integrated renewable products company applying industrial synthetic biology to genetically modify microorganisms to serve as living factories. Amyris designs these microorganisms to produce defined molecules for use as renewable chemicals and transportation fuels. The Company is engaged in the development of farmesene- a molecule, which serves as the base chemical building block for a wide range of renewable products to replace existing products that are derived from petroleum, plant or animal sources and that may be of lower quality or higher price. Amyris INC is headquartered in Emeryville, CA. “
Other equities research analysts also recently issued reports about the company. HC Wainwright set a $15.00 target price on Amyris and gave the stock a buy rating in a report on Wednesday, November 29th. B. Riley started coverage on Amyris in a report on Thursday, January 25th. They issued a buy rating and a $8.00 target price on the stock. Cowen reissued a hold rating and issued a $4.00 target price on shares of Amyris in a report on Wednesday, November 29th. Finally, ValuEngine raised Amyris from a strong sell rating to a sell rating in a report on Friday, February 23rd. One equities research analyst has rated the stock with a sell rating, two have given a hold rating and two have assigned a buy rating to the company’s stock. Amyris presently has a consensus rating of Hold and a consensus target price of $7.69.
In other news, insider John Melo sold 10,776 shares of the company’s stock in a transaction on Tuesday, January 16th. The stock was sold at an average price of $4.68, for a total transaction of $50,431.68. Following the transaction, the insider now directly owns 83,172 shares of the company’s stock, valued at $389,244.96. The sale was disclosed in a filing with the SEC, which is available at the SEC website. Corporate insiders own 11.30% of the company’s stock.
Several large investors have recently made changes to their positions in AMRS. Carl Domino Inc bought a new position in shares of Amyris during the third quarter valued at $182,000. Creative Planning bought a new position in shares of Amyris during the fourth quarter valued at $188,000. KBC Group NV lifted its holdings in shares of Amyris by 228.4% during the third quarter. KBC Group NV now owns 60,154 shares of the biotechnology company’s stock valued at $192,000 after purchasing an additional 41,834 shares in the last quarter. Compagnie Lombard Odier SCmA lifted its holdings in shares of Amyris by 60.0% during the fourth quarter. Compagnie Lombard Odier SCmA now owns 104,000 shares of the biotechnology company’s stock valued at $390,000 after purchasing an additional 39,000 shares in the last quarter. Finally, Hudson Bay Capital Management LP bought a new position in shares of Amyris during the fourth quarter valued at $451,000. 22.40% of the stock is currently owned by hedge funds and other institutional investors.
COPYRIGHT VIOLATION NOTICE: This piece was originally reported by Week Herald and is the property of of Week Herald. If you are reading this piece on another site, it was stolen and republished in violation of U.S. and international copyright & trademark laws. The original version of this piece can be read at https://weekherald.com/2018/03/14/amyris-amrs-stock-rating-upgraded-by-zacks-investment-research.html.
Amyris Company Profile
Amyris, Inc is an integrated industrial biotechnology company. The Company is engaged in research and development and sales of fuels and farnesene-derived products. It is applying its industrial synthetic biology platform to engineer, manufacture and sell products into a range of consumer and industrial markets, including cosmetics, flavors and fragrances (F&F), solvents and cleaners, polymers, lubricants, healthcare products and fuels.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Amyris Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amyris and related companies with MarketBeat.com's FREE daily email newsletter.